Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Subscribe To Our Newsletter & Stay Updated
